Kevin Heller

Dr. Kevin Heller is Chief Medical Officer at Tallac Therapeutics, a physician-scientist and drug developer with over 20 years of experience in oncology research in academia and industry.

Kevin Heller is a biotech executive, physician-scientist, and drug developer with over 20 years of experience in oncology research in academia and industry. His experience spans across all stages of oncology drug development from discovery (academia) and pre-IND through commercialization and business development. He participated in the development of multiple FDA approved drugs. He received his Bachelor’s degree in molecular biophysics and biochemistry from Yale University and his medical degree from George Washington University before training first in pediatrics and then pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center. Following his fellowship, Dr. Heller joined the faculty at Rockefeller University as Instructor and subsequently Chief Clinical Scholar of Clinical Investigation in the laboratory of Ralph Steinman. During this time, he served as principal investigator on clinical trials, including conducting research into T-cell mediated immune responses among patients with EBV-mediated lymphomas.

Kevin is an alumnus of the Science Talent Search 1989.